On October 20, 2022, ChemoCentryx completed its merger with Carnation Merger Sub, Inc. (“Merger Sub”), a Delaware corporation and a wholly owned subsidiary of Amgen Inc., a Delaware corporation (“Amgen”), whereby Merger Sub merged with and into ChemoCentryx, with ChemoCentryx continuing as the surviving corporation and a wholly owned subsidiary of Amgen (the “Merger”). The Merger was effected pursuant to an Agreement and Plan of Merger, dated as of August 3, 2022, among ChemoCentryx, Amgen, and Merger Sub (the “Merger Agreement”). In connection with the Merger, at the Effective Time, each member of the Board submitted his or her resignation from the Board and from all committees of the Board on which such directors served.

The members of the Board immediately prior to the Effective Time were Thomas J. Schall, Ph.D., Thomas A. Edwards, Joseph M. Feczko, M.D., Jennifer L. Herron, Rita I. Jain, M.D., Susan M. Kanaya, Geoffrey M. Parker, James L. Tyree, and David E. Wheadon, M.D. In connection with the Merger, at the Effective Time, each executive officer of ChemoCentryx submitted his or her resignation from his or her position as an executive officer of ChemoCentryx. The officers of ChemoCentryx immediately prior to the Effective Time were Thomas J. Schall, Ph.D., Tausif Butt, Rita I. Jain, M.D., Markus J. Cappel, Ph.D., and Susan M. Kanaya.